Otrivine Décongestionnant (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Otrivine Décongestionnant, is a alpha‑adrenergic agonist presented as a nasal spray for intranasal use. It relieves nasal congestion caused by colds, sinusitis, or allergic rhinitis in adults and children when appropriate.

GNH USA supplies Otrivine Décongestionnant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a topical nasal decongestant that reduces swelling of the nasal mucosa. - Common cold: provides rapid relief of nasal blockage caused by viral upper‑respiratory infection. - Acute sinusitis: eases congestion and improves sinus drainage during the early phase of sinus inflammation. - Allergic rhinitis: diminishes nasal swelling associated with seasonal or perennial allergic reactions.

Adverse reactions may occur following intranasal administration of Xylometazoline Hydrochloride.

Common Side Effects: - Nasal irritation or burning sensation - Sneezing - Dryness of the nasal mucosa - Headache - Mild epistaxis (nosebleed)

Serious or Rare Side Effects: - Rebound congestion with prolonged use (>3‑5 days) - Hypertension or elevated blood pressure - Palpitations or tachycardia - Severe allergic reaction (anaphylaxis) - Persistent nasal ulceration

Before using Otrivine Décongestionnant, consider the following safety measures. - Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Pregnancy: consult a healthcare professional before use, as safety data are limited. - Children: follow pediatric guidance; avoid use in infants under six months. - Drug interactions: review concomitant sympathomimetic agents with a prescriber. - Store at below 25°C: keep the bottle in its original packaging, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride may interact with other medications that affect the sympathetic nervous system.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Systemic decongestants (e.g., pseudoephedrine): additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt cardiovascular response. - Antihypertensive agents: possible reduction in blood‑pressure‑lowering effect. - Tricyclic antidepressants: potential for increased sympathetic activity.